Effect of sodium‐glucose cotransporter‐2 inhibitors on myocardial infarction incidence: A systematic review and meta‐analysis of randomized controlled trials and cohort studies
Authors' conclusion
In both RCTs and cohort studies, SGLT2 inhibitors reduced MI incidence. The cardioprotective effects of SGLT2 inhibitors were observed in patients with and without a history of CVD.
Study context
- Population
- Patients with or without T2D; Randomized controlled trials (RCTs) and cohort studies reporting effects of SGLT2i on myocardial infarction (MI) incidence, searched up to 7 May 2022
- Participants
- 3,394,423 patients54 RCTs32 cohort studies
- Comparison
- SGLT2i vs control
- Outcome
- MI incidence
Methodological detailssubgroup analysis, meta-regression
- Subgroup analysis
- Meta-regression
Pooled result
As reported in the abstract
SGLT2i vs ControlRelative risk (95% CI)
RCTs
0.9(0.84–0.96)
Cohort studies
0.89(0.83–0.94)
Further pooled results
MI incidence, subgroups in RCTs (SGLT2i type, control drug type, cardiovascular disease (CVD) status, source of outcome extraction)
- No significant alterations in outcomes across subgroups
- P for interaction > 0.05
MI incidence by CVD status, cohort studies
- Similar effects with or without CVD
- P for interaction = 0.179
MI incidence by type of control group, cohort studies
- Variations in results by type of control group
- P for interaction = 0.036
Meta-regression
- No association between baseline cardiovascular risk factors, follow-up length, or MI incidence
Original publication
Effect of sodium‐glucose cotransporter‐2 inhibitors on myocardial infarction incidence: A systematic review and meta‐analysis of randomized controlled trials and cohort studies. Diabetes Obes Metab. Published 12 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →